犬類疫苗市場機會、成長要素、產業趨勢分析及2026-2035年預測。

預計到 2025 年，全球犬用疫苗市場價值將達到 25 億美元，並有望以 7.3% 的複合年成長率成長，到 2035 年達到 52 億美元。

寵物健康意識的提高、狂犬病、犬細小病毒和犬瘟熱等犬類疾病發病率的上升以及對預防性保健日益重視，共同推動了疫苗接種的普及。隨著全球寵物犬數量的增加，寵物飼主越來越重視疫苗接種計劃，以保護狗狗免受危及生命的疾病。犬類疫苗是生物製藥，利用模擬病原體但不會引起感染的抗原，刺激免疫系統辨識並抵抗特定病原體。政府主導的舉措，例如疫苗津貼宣傳活動和公共衛生宣傳項目，在提高疫苗接種率方面發揮著至關重要的作用。這些措施不僅能遏止疾病傳播，還能促進寵物健康，鼓勵定期接種疫苗，並強化犬隻預防保健的整體重要性。

預計到2025年，活病毒疫苗市場規模將達到11億美元。活病毒疫苗含有減毒病原體，能夠誘發強效且持久的免疫反應，而不會引起疾病。它們能高效誘導細胞免疫和體液免疫，提供多種犬類疾病的全面保護。由於接種次數少，活疫苗為獸醫和寵物飼主帶來了便利，因此廣受歡迎，成為理想的疫苗接種選擇。

到2025年，注射疫苗將佔據75%的市場。注射疫苗因其可精準給藥並能誘發穩定的免疫反應而廣受歡迎。在專家的指導下，這些疫苗能夠提供可靠的保護，並在常規獸醫護理中擁有良好的臨床記錄。注射疫苗配方的持續創新進一步推動了其應用，並使其成為全球犬類免疫計畫的基礎。

到2025年，北美犬用疫苗，在醫療保健服務方面的支出也相當可觀，這為定期接種疫苗提供了支持。此外，嚴格的免疫接種法規和完善的醫療保健網路鼓勵犬飼主遵循建議的疫苗接種計劃，從而有效預防狂犬病、犬瘟熱和犬細小病毒等疾病。先進的醫療保健服務以及消費者日益成長的寵物健康投資意願，進一步鞏固了北美在犬用疫苗市場的主導地位。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章業界考察

• 生態系分析
• 影響產業的因素
  • 促進因素
    • 犬隻數量和寵物擁有率不斷增加
    • 人們對預防獸醫學的認知不斷提高
    • 政府法規和強制接種疫苗
    • 擴大獸醫保健基礎設施
    • 寵物醫療保健支出增加
  • 產業潛在風險與挑戰
    • 部分地區獸醫費用上漲
    • 低溫運輸儲存和配送面臨的挑戰
  • 市場機遇
    • 多價疫苗和聯合疫苗的研發
    • 擴大寵物預防保健計劃
• 成長潛力分析
• 監理情勢（基於初步調查）
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
  • 亞太地區
• 科技與創新趨勢
  • 目前技術
  • 新興技術（基於初步調查）
• 臨床試驗和研發管線分析（基於初步調查）
• 專利分析（基於初步研究）
• 各國養狗統計數據
• 未來市場趨勢
• 人工智慧和生成式人工智慧對市場的影響
• 波特五力分析
• PESTEL 分析

第4章 競爭情勢

• 介紹
• 企業市佔率分析
• 企業矩陣分析
• 主要市場公司的競爭分析
• 競爭定位矩陣
• 主要進展
  • 併購
  • 夥伴關係與合作
  • 新產品發布
  • 業務拓展計劃

第5章 市場估計與預測：疫苗類型，2022-2035年

• 活病毒疫苗
• 失活
• 重組
• 其他疫苗類型

第6章 市場估計與預測：依疾病分類，2022-2035年

• 犬瘟熱
• 犬傳染性呼吸道疾病症候群（CIRDC）
• 犬小病毒
• 犬鉤端螺旋體病
• 犬萊姆病
• 犬傳染性肝炎
• 犬狂犬病
• 其他疾病類型

第7章 市場估計與預測：依給藥途徑分類，2022-2035年

• 鼻內
• 注射藥物
• 口服

第8章 市場估算與預測：依最終用途分類，2022-2035年

• 動物醫院
• 動物醫院
• 研究機構

第9章 市場估計與預測：依地區分類，2022-2035年

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 日本
  • 中國
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 沙烏地阿拉伯
  • 南非
  • 阿拉伯聯合大公國

第10章：公司簡介

• Bioveta
• Boehringer Ingelheim International
• Brilliant Bio Pharma
• Biogenesis Bago
• Ceva Sante Animale
• Elanco Animal Health Incorporated
• HIPRA
• Indian Immunologicals Limited
• Merck & Co., Inc.
• NEOTECH
• Tecnovax
• Virbac
• Zendal Group
• Zoetis

The Global Dog Vaccine Market was valued at USD 2.5 billion in 2025 and is estimated to grow at a CAGR of 7.3% to reach USD 5.2 billion by 2035.

The expansion is fueled by increasing awareness of pet health, rising incidences of canine diseases such as rabies, parvovirus, and distemper, and a growing emphasis on preventive healthcare. As dog ownership rises worldwide, pet owners are prioritizing vaccination programs to protect their animals from life-threatening illnesses. Dog vaccines are biological formulations that stimulate the immune system to recognize and defend against specific pathogens, using antigens that mimic disease agents without causing infection. Government initiatives, including subsidized vaccination campaigns and public health awareness programs, play a crucial role in increasing immunization coverage. These measures not only reduce disease prevalence but also promote healthier pet populations, encouraging regular vaccination schedules and reinforcing the overall importance of canine preventive care.

The live attenuated segment generated USD 1.1 billion in 2025. Live attenuated vaccines contain weakened pathogens that trigger a strong and long-lasting immune response without causing illness. They are highly effective in inducing both cellular and humoral immunity, providing comprehensive protection against multiple canine diseases. Their requirement for fewer doses enhances convenience for veterinarians and pet owners, which contributes to their widespread adoption as the preferred vaccination option.

The injectable segment accounted for 75% share in 2025. Injectable vaccines are widely preferred due to their ability to deliver precise dosages and generate consistent immune responses. Administered under professional supervision, these vaccines provide reliable protection and have a well-established clinical record in routine veterinary practice. Continuous innovations in injectable vaccine formulations are further driving adoption, making them the cornerstone of canine immunization programs worldwide.

North America Dog Vaccine Market held a 45.7% share in 2025. High pet ownership, strong veterinary healthcare infrastructure, and widespread awareness of preventive care drive this growth. The region's large dog population and substantial spending on veterinary services support regular immunization practices. Moreover, strict vaccination regulations and comprehensive veterinary networks encourage dog owners to adhere to recommended schedules, ensuring protection against diseases like rabies, distemper, and parvovirus. Advanced healthcare services and growing consumer willingness to invest in pet wellbeing reinforce North America's leadership position in the dog vaccine market.

Key players operating in the Global Dog Vaccine Market include Bioveta, Boehringer Ingelheim International, Brilliant Bio Pharma, Biogenesis Bago, Ceva Sante Animale, Elanco Animal Health Incorporated, HIPRA, Indian Immunologicals Limited, Merck & Co., Inc., NEOTECH, Tecnovax, Virbac, Zendal Group, and Zoetis. Companies in the Dog Vaccine Market are implementing diverse strategies to strengthen their market presence and expand their foothold. They are investing heavily in research and development to enhance vaccine efficacy, create novel formulations, and extend protection against emerging canine diseases. Strategic collaborations with veterinary networks, animal healthcare providers, and government initiatives help increase product reach and vaccination coverage. Geographic expansion into high-demand regions ensures access to growing pet populations, while digital platforms and tele-veterinary services improve distribution and awareness. Firms also focus on sustainability by optimizing production processes and packaging solutions. Product diversification, including combination vaccines, booster programs, and temperature-stable formulations, enables companies to meet evolving customer needs, maintain competitive advantage, and reinforce brand loyalty across global markets.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research approach
• 1.3 Quality commitments
  • 1.3.1 GMI AI policy and data integrity commitment
    • 1.3.1.1 Source consistency protocol
• 1.4 Research trail and confidence scoring
  • 1.4.1 Research trail components
  • 1.4.2 Scoring components
• 1.5 Data collection
  • 1.5.1 Partial list of primary sources
• 1.6 Data mining sources
  • 1.6.1 Paid sources
    • 1.6.1.1 Sources, by region
• 1.7 Base estimates and calculations
  • 1.7.1 Revenue share analysis
  • 1.7.2 Base year calculation
• 1.8 Forecast model
• 1.9 Research transparency addendum
  • 1.9.1 Source attribution framework
  • 1.9.2 Quality assurance metrics
  • 1.9.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Vaccine type trends
  • 2.2.3 Disease type trends
  • 2.2.4 Route of administration trends
  • 2.2.5 End use trends
• 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising dog population and pet ownership
    • 3.2.1.2 Growing awareness of preventive veterinary care
    • 3.2.1.3 Government regulations and vaccination mandates
    • 3.2.1.4 Expansion of veterinary healthcare infrastructure
    • 3.2.1.5 Increasing expenditure on pet healthcare
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of veterinary care in some regions
    • 3.2.2.2 Cold-chain storage and distribution challenges
  • 3.2.3 Market opportunities
    • 3.2.3.1 Development of multivalent and combination vaccines
    • 3.2.3.2 Expansion of preventive pet healthcare programs
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape (Driven by Primary Research)
  • 3.4.1 North America
    • 3.4.1.1 U.S.
    • 3.4.1.2 Canada
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
• 3.5 Technology and innovation landscape
  • 3.5.1 Current technologies
  • 3.5.2 Emerging technologies (Driven by Primary Research)
• 3.6 Clinical trial/pipeline analysis (Driven by Primary Research)
• 3.7 Patent analysis (Driven by Primary Research)
• 3.8 Dog population stats, by country
• 3.9 Future market trends
• 3.10 Impact of AI and generative AI on the market
• 3.11 Porter's analysis
• 3.12 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Vaccine Type, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Live attenuated
• 5.3 Inactivated
• 5.4 Recombinant
• 5.5 Other vaccine types

Chapter 6 Market Estimates and Forecast, By Disease Type, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Canine distemper
• 6.3 Canine infectious respiratory disease complex (CIRDC)
• 6.4 Canine parvovirus
• 6.5 Canine leptospirosis
• 6.6 Canine lyme disease
• 6.7 Infectious canine hepatitis
• 6.8 Canine rabies
• 6.9 Other disease types

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Intranasal
• 7.3 Injectable
• 7.4 Oral

Chapter 8 Market Estimates and Forecast, By End Use, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 Veterinary hospitals
• 8.3 Veterinary clinics
• 8.4 Research institutes

Chapter 9 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 South Africa
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Bioveta
• 10.2 Boehringer Ingelheim International
• 10.3 Brilliant Bio Pharma
• 10.4 Biogenesis Bago
• 10.5 Ceva Sante Animale
• 10.6 Elanco Animal Health Incorporated
• 10.7 HIPRA
• 10.8 Indian Immunologicals Limited
• 10.9 Merck & Co., Inc.
• 10.10 NEOTECH
• 10.11 Tecnovax
• 10.12 Virbac
• 10.13 Zendal Group
• 10.14 Zoetis